尿毒清颗粒联合氯沙坦治疗糖尿病肾病的临床观察被引量：3

下载PDF

导出

摘要目的观察尿毒清颗粒联合氯沙坦治疗糖尿病肾病(DN)致肾功能衰竭的疗效。方法联合应用尿毒清颗粒和氯沙坦片为治疗组,与对照组相比,分别测定治疗前后患者的肾功能及24 h尿蛋白定量。结果治疗组能使尿蛋白排泄减少,血BUN、Scr较前改善(P<0.05),改善肾功能。结论尿毒清颗粒联合氯沙坦是治疗DN所致的CRF患者早期非透析疗法的较好药物,尤其在血SCr超过256umol/L时,不宜使用ACEI类药物时,使用氯沙坦取得较好效果。

作者于建红

机构地区福建省建阳市立医院内一科

出处《中国卫生产业》 2013年第34期183-183,185,共2页 China Health Industry

关键词尿毒清颗粒氯沙坦糖尿病肾病

分类号 R285.6 [医药卫生—中药学]

引文网络
相关文献

参考文献7

1Fan QL, Yang G, Liu XD, et al. Effect of losartan on the glomerular pro-tein expression profile of type 2 diabetic KKAy mice[J]. J Nephrol,2013,26(3):517-526. doi: 10.5301/jn.5000176.
2Nicholas SB, Iyengar SK. Does losartan prevent progression of early dia-betic nephropathy in american indians with type 2 diabetes [J].Diabetes.2013,62(9):3014-3016. doi: 10.2337/db 13-0748.
3廉开胜.中药灌肠联合尿毒清颗粒治疗慢性肾功能衰竭疗效观察[J].浙江中西医结合杂志,2010,20(9):551-553. 被引量：5
4李璇,王琼,何宝,孙雪莹,孙小玉,李晓冬,朱荃.尿毒清颗粒改善链佐星-弗氏完全佐剂诱导的糖尿病肾病模型肾脏功能的研究[J].中成药,2010,32(9):1483-1488. 被引量：6
5Liu Y, Jia Z,Liu S, et al. Combined Losartanand Nitro-Oleic Acid Re-markably Improves Diabetic Nephropathy in Mice[J]. Am J Physiol RenalPhysiol, 2013,14.
6Weil EJ, Fufaa G, Jones LI, et al. Effect of losartan on prevention andprogression of early diabetic nephropathy?in american indians with type2 diabetes [J]. Diabetes,2013,62 (9):3224-3231. doi: 10.2337/dbl2~1512.
7Mavroeidi V, Petrakis I,Stylianou K, et ai. Losartan affects glomerularAKT and mTOR phosphorylation in an experimental model of type 1 dia-betic nephropathy [J]. J Histochem Cytochem, 2013,61 (6):433 -443. doi:10.1369/0022155413482925.

二级参考文献15

1卢腾.尿毒清治疗慢性肾功能不全42例疗效观察[J].现代医药卫生,2007,23(5):721-722. 被引量：9
2李玉卿,周锦明.90张慢性肾功能衰竭灌肠方组方分析[J].现代中西医结合杂志,2007,16(12):1661-1662. 被引量：19
3Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history[ J ]. Curr Diab Rep, 2006, 6:479-483.
4Jafar T H, Schmid C H, Levey A S. Serum creatinine as maker of kidney function in south Asians: a study of reduced GFR in adults in Pakistan[J]. J Am Soc Nephrol, 2005, 16:1413-1419.
5Hisashi M, Yoshihiro M, Kazutomo S, et al. Shin-ichi S altered gene expression related to glomerulogencsis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone[ J]. Diabetes, 2006, 55:2747-2756.
6Gupta S, Chough E, Daley J, et al. Ruderman NB, et al. Hyperglycemia increases endothelial superoxide that impairs smooth muscle cell Na^+ -K ^+ -ATPase activity [ J ]. Am J Physiol Cell Physiol, 2002, 282 :C560-C566.
7Bilous R W, Mauer S M, Sutherland D E, et al. Mean glomerular volume and rate of development of diabetic nephropathy [ J ]. Diabetes, 1989, 38 : 1142-1147.
8Munch G, Keis R, Wessels A, et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA[J]. Eur J Clin Chem Clin Biochem, 1997, 35 : 669-677.
9Parvanova A I, Trevisan R, Iliev I P, et al. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion [ J ]. Diabetes, 2006, 55 : 1456-1462.
10Goldin A, Beckman J A, 5chmidt A M, et al. Advanced glycation end products: sparking the development of diabetic vascular injury [ J ]. Circulation, 2006,114 : 597-605.